Showing results (71-80 of 134) with videos related to
Sort By:
Pageof 14
Journal of Otolaryngology - Head & Neck Surgery = Le Journal D'Oto-Rhino-Laryngologie Et De Chirurgie Cervico-Faciale|May 14, 2013
Primary surgery versus chemoradiotherapy for advanced oropharyngeal cancers: a longitudinal population studyDaniel O'Connell, Hadi Seikaly, Russell Murphy, et al.Frontiers in Oncology|February 11, 2020
Differential Outcomes and Biologic Markers of Radiation-Associated vs. Sporadic Osteosarcoma: A Single-Institution ExperienceBrittany L Siontis, Jonathan B McHugh, Emily Roberts, et al.Journal of Otolaryngology - Head & Neck Surgery = Le Journal D'Oto-Rhino-Laryngologie Et De Chirurgie Cervico-Faciale|February 5, 2022
Development of a patient reported outcome instrument for chronic sialadenitisFatemeh Ramazani, Amr Hamour, Caroline C Jeffery, et al.Journal of Community Health|October 22, 2018
Understanding Geographic and Neighborhood Variations in Overdose Death RatesJascha Wagner, Logan Neitzke-Spruill, Daniel O'Connell, et al.Trials|May 30, 2015
Intraoperative brief electrical stimulation (BES) for prevention of shoulder dysfunction after oncologic neck dissection: study protocol for a randomized controlled trialBrittany Barber, Margaret McNeely, K Ming Chan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2004
Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcomaKirsten M Leu, Leo J Ostruszka, Donna Shewach, et al.Oncotarget|April 21, 2017
Next generation sequencing of extraskeletal myxoid chondrosarcomaElizabeth J Davis, Yi-Mi Wu, Dan Robinson, et al.Cancer|April 28, 2007
Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcomaRashmi Chugh, Thomas Wagner, Kent A Griffith, et al.Medical Care|January 26, 2012
Prioritization in comparative effectiveness research: the CANCERGEN ExperienceRahber Thariani, William Wong, Josh J Carlson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004
Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcomaFrancis P Worden, Jeremy M G Taylor, Janet S Biermann, et al.Pageof 14